Health Canada recalls semaglutide drugs made by compounding pharmacy
Global News
Health Canada is recalling compounded drugs containing semaglutide, which is a key component in popular medications like Ozempic and Wegovy.
Health Canada is recalling compounded drugs containing semaglutide, which is a key component in popular medications like Ozempic and Wegovy.
The drugs were compounded by Alberta-based Create Compounding Pharmacy and comprised semaglutide, which belongs to the GLP-1 class of drugs, and pyridoxine, which is a form of vitamin B6.
“The product was produced with an unauthorized active pharmaceutical ingredient,” Health Canada said in the recall published Tuesday.
The drugs were sold in syringe or vial form.
Compounding is when pharmacies or other practitioners have the substances needed to mix and prepare specialty medications, and do so. It was frequently used in Canada by pharmacies during the COVID-19 pandemic when manufactured supplies of children’s pain medications were in short supply but the pharmaceutical components to mix those medications were still available in some pharmacies.
It is only meant to be done in cases where there is limited supply of a medication “and should not be done solely for economic reasons for the healthcare professionals,” according to Health Canada guidelines on compounding.
Ozempic maker Novo Nordisk says it’s the only company in Canada with Health Canada-approved products containing semaglutide.
Novo Nordisk told Global News last summer that it had filed a complaint with Health Canada regarding the promotion and sale of compounded semaglutide.